Overview
Alzheimer’s disease (AD) and Parkinson’s disease (PD) are the two most common neurodegenerative diseases. In AD, β-amyloid (Aβ) plaques and neurofibrillary tangles (NFTs) are accompanied by neuronal loss, synaptic dysfunction, brain atrophy, and inflammation manifested as glial activation. Amnestic mild cognitive impairment (MCI) is a transitional stage between cognitively normal and AD. There is an intense debate on whether neuroinflammation is a primary or secondary event in neurodegenerative diseases.
The aim of this research study is to evaluate novel brain inflammation tracer, GE180 seen in Alzheimer’s disease and mild cognitive impairment subjects patients. With this study we hope to learn more about the changes that occur in the brain in people with AD and mild cognitive impairment. We hope this information will help us to develop effective preventative treatments in the future.
Researchers involved
- Paul Edison
- Melanie Dani
- Valeria Calsolaro
- Daniela Femminella
- Zhen Fan
- Rebecca Atkinson
- Kathy Bouanane